Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
TR
Traws Pharma, Inc. Common Stock
TRAW
Volume
257.25K
Next Earnings
November 12th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
TR
TRAW
TR
Traws Pharma, Inc. Common Stock
TRAW
News
·
Traws Pharma Provides Regulatory Update on Influenza Program
Mkt Cap
$6.2M
Volume
257.25K
Next Earnings
November 12th
Chart
Financials
Earnings
News
About
Insider
Filings
Traws Pharma Provides Regulatory Update on Influenza Program
Traws Pharma announced the deferral of its Phase 2a human influenza challenge study for tivoxavir marboxil (TXM) following a negative regulatory review by the UK's MHRA. While the compound showed potent efficacy in animal models, the company is advancing backup candidates with similar pharmacokinetic profiles while maintaining cash runway through Q1 2027.
GlobeNewswire Inc. · Jun 12, 2026
Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025
Traws Pharma initiated Phase 2 clinical trials for ratutrelvir, a ritonavir-free COVID-19 treatment, comparing its safety and efficacy against PAXLOVID®. The company expects to report trial results by year-end 2025, targeting potential improvements in COVID treatment.
GlobeNewswire Inc. · Oct 14, 2025
Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025
Traws Pharma, a clinical-stage biopharmaceutical company, is developing novel antiviral therapies targeting respiratory viral diseases like bird flu, seasonal influenza, and COVID-19. The company submitted a Phase 2 protocol for tivoxavir marboxil and briefing documents to the FDA for a Type D meeting.
GlobeNewswire Inc. · Aug 8, 2025
Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib
Traws Pharma announces the publication of positive clinical data for its legacy oncology drug rigosertib in treating recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma (RDEB SCC), a rare and aggressive form of skin cancer.
GlobeNewswire Inc. · Jun 3, 2025
Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update
Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire Inc. · May 16, 2024
Heron Therapeutics (HRTX) Reports Q1 Loss, Tops Revenue Estimates
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 75% and 6.68%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research · May 7, 2024
Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy
Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy
GlobeNewswire Inc. · May 7, 2024
Why Flora Growth Shares Are Trading Lower By Around 20%; Here Are 20 Stocks Moving Premarket
Shares of Flora Growth Corp. (NASDAQ: FLGC) fell sharply in today’s pre-market trading after the company reported the launch of proposed underwritten public offering of common shares. Flora Growth shares tumbled 20.2% to $2.13 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers HWH International Inc. (NASDAQ: HWH) rose 175% to $4.32 in pre-market trading. Zhongchao Inc. (NASDAQ: ZCMD) gained 43% to $2.18 in pre-market trading after gaining 22% on Wednesday. Brooge Energy Limited (NASDAQ: BROG) gained 26.4% to $2.39 in pre-market trading after dipping over 20% on Wednesday. Sintx Technologies, Inc. (NASDAQ: SINT) shares rose 23.5% to $0.0284 in pre-market trading. SiNtx Technologies shares fell around 45% on Wednesday after the company announced pricing of a $1.5 million public offering of common stock. Addex Therapeutics Ltd (NASDAQ: ADXN) shares rose 15.1% to $17.84 in pre-market trading. Addex Therapeutics shares gained 18% on Wednesday after the company and funds affiliated with Perceptive Advisors announced the launch of Neurosterix.. Destiny Tech100 Inc. (NASDAQ: DXYZ) shares ...
Benzinga · Apr 4, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
TR
TRAW
Traws Pharma, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
TRAW
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any TRAW yet.
Related Tickers
DR
DRCT
—
SL
SLGL
—
Earnings